Journal of Anesthesia

, Volume 26, Issue 4, pp 601–605 | Cite as

Use of dexmedetomidine for the treatment of alcohol withdrawal syndrome in critically ill patients: a retrospective case series

  • Jonas P. DeMuro
  • David G. Botros
  • Ela Wirkowski
  • Adel F. Hanna
Clinical Report

Abstract

Alcohol withdrawal syndrome (AWS) continues to be a challenge to manage in the ICU setting, and the ideal pharmacological treatment continues to evolve. Dexmedetomidine is a newer agent approved for short-term sedation in the ICU, but its use in the treatment of AWS has been limited. We report a retrospective case series of ten patients who were identified as receiving dexmedetomidine for AWS as designated by electronic pharmacy records. All subjects were male, with a mean age of 53.6 years, and a mean ICU length of stay of 9.3 days. They were all diagnosed with AWS by DSM-IV criteria. All the study patients received dexmedetomidine during their hospital course as a treatment for AWS. Studied variables included demographic data, dose and duration of dexmedetomidine, other pharmaceutical agents, and hemodynamics. Dexmedetomidine was safe to use in all patients, although mechanical ventilation was still required in three patients. With dexmedetomidine, the autonomic hyperactivity was blunted, with a mean 12.8 % reduction in rate pressure product observed. Consideration should be given to the combined use of dexmedetomidine with benzodiazepines in the treatment of AWS.

Keywords

Dexmedetomidine Alcohol withdrawal syndrome Pharmacological therapy Alcohol Critical care 

Notes

Acknowledgments

The authors have no financial or ethical interests to disclose relevant to this submission. There was no financial support for this study from any source, institutional or outside.

References

  1. 1.
    Kaim SC, Klett CJ, Rothfeld B. Treatment of the acute alcohol withdrawal state: a comparison of four drugs. Am J Psychiatry. 1969;125:1640–6.PubMedGoogle Scholar
  2. 2.
    Sarff M, Gold J. Alcohol withdrawal syndromes in the intensive care unit. Crit Care Med. 2010;38(suppl):S494–S501.Google Scholar
  3. 3.
    Kosten TR, O’Connor PG. Management of drug and alcohol withdrawal. N Engl J Med. 2003;348:1786–95.PubMedCrossRefGoogle Scholar
  4. 4.
    Cushman P Jr. Clonidine and alcohol withdrawal. Adv Alcohol Subst Abuse. 1987;7:17–28.Google Scholar
  5. 5.
    Kamibayashi T, Maze M. Clinical uses of α2-adrenergic agonists. Anesthesiology. 2000;93:1345–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Gerlach AT, Dasta JF. Dexmedetomidine: an updated review. Ann Pharmacother. 2007;41:245–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Abramov D, Nogid B, Nogid A. The role of dexmedetomidine (Precedex) in the sedation of critically ill patients. P&T. 2005;30:158–61.Google Scholar
  8. 8.
    Lakhlani PP, MacMillan LB, Guo TZ, McCool BA, Lovinger DM, Maze M, Limbird LE. Substitution of a mutant a2A-adrenergic receptor via ‘hit and run’ gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc Natl Acad Sci USA. 1997;94:9950–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Dexemetomidine (package insert). Lake Forest: Hospira, Inc.; 2008.Google Scholar
  10. 10.
    Reiter PD, Pietras M, Dobyns EL. Prolonged dexmedetomidine infusions in critically ill infants and children. Indian Pediatr. 2009;46:767–73.PubMedGoogle Scholar
  11. 11.
    Riihioja P, Jaatinen P, Oksanen H, Haapalinna A, Heinonen E, Hervonen A. Dexmedetomidine, diazepam, and propanolol in the treatment of ethanol withdrawal symptoms in the rat. Alcohol Clin Exp Res. 1997;21:804–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Riihioja P, Jaatinen P, Haapalinna A, Kiianmaa K, Hervonen A. Effects of dexmedetomidine on rat locus coeruleus and ethanol withdrawal symptoms during intermittent ethanol exposure. Alcohol Clin Exp Res. 1999;23:432–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Le AD, Harding S, Juzytsch W, Funk D, Shaham Y. Role of alpha-2 adrenoreceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats. Psychopharmacology. 2005;179:366–73.PubMedCrossRefGoogle Scholar
  14. 14.
    Darrouj J, Puri N, Prince E, Lomonaco A, Spevetz A, Gerber DR. Dexmedetomidine infusion as adjunctive therapy to benzodiazepines for acute alcohol withdrawal. Ann Pharmacother. 2008;42:1703–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Maccioli GA. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology. 2003;98:575–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Rovasalo A, Tohmo H, Aantaa R, Kettunen E, Palojoki R. Dexmedetomidine as an adjuvant in the treatment of alcohol withdrawal delirium: a case report. Gen Hosp Psychiatry. 2006;28:362–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Baddigam K, Russo P, Russo J, Tobias J. Dexmedetomidine in the treatment of withdrawal syndromes in cardiothoracic surgery patients. J Intensive Care Med. 2005;20:118–23.PubMedCrossRefGoogle Scholar
  18. 18.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn., text revision. Washington, DC: American Psychiatric Association; 2000. p. 216.Google Scholar
  19. 19.
    Jones R, Knight PR, Hill AB. Rate pressure product. Anaesthesia. 1980;35:1010–1.PubMedCrossRefGoogle Scholar
  20. 20.
    Williams D, McBride AJ. The drug treatment of alcohol withdrawal symptoms: a systematic review. Alcohol Alcohol. 1998;33:103–15.PubMedGoogle Scholar

Copyright information

© Japanese Society of Anesthesiologists 2012

Authors and Affiliations

  • Jonas P. DeMuro
    • 1
  • David G. Botros
    • 1
  • Ela Wirkowski
    • 2
  • Adel F. Hanna
    • 1
  1. 1.Division of Trauma and Critical Care, Department of SurgeryWinthrop University HospitalMineolaUSA
  2. 2.Neurosciences Special Care Unit, Department of NeurosciencesWinthrop University HospitalMineolaUSA

Personalised recommendations